Bavarian Nordic A/S ( (BVNRY) ) has released its Q3 earnings. Here is a breakdown of the information Bavarian Nordic A/S presented to its investors.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Bavarian Nordic A/S is a global vaccine company specializing in the development and production of vaccines for infectious diseases, with a strong focus on travel health and public preparedness sectors.
Bavarian Nordic has reported a robust financial performance for the first nine months of 2025, with a 32% increase in revenue to DKK 4,793 million, driven by strong demand in both its Travel Health and Public Preparedness segments. The company also highlighted significant progress in the global launch of its chikungunya vaccine, Vimkunya, and the completion of a lucrative sale of a Priority Review Voucher.
Key financial metrics include a 23% increase in Travel Health revenue, primarily due to rabies and tick-borne encephalitis vaccines, and a notable 51% growth in Public Preparedness revenue. The company’s EBITDA before special items reached DKK 1,477 million, with a margin of 31%. Strategic achievements include the expansion of Vimkunya’s market presence across Europe and securing a substantial contract for smallpox/mpox vaccines with the European Commission.
Looking ahead, Bavarian Nordic remains optimistic about meeting its financial targets for 2025, with expected total revenue of approximately DKK 6,000 million and an EBITDA margin of around 26% before special items. The company is poised for continued growth, supported by secured contracts and strategic partnerships, as it navigates the evolving landscape of global health preparedness.